Flexion Therapeutics Profile

27.42
USD 0.03  0.11%
96%
30%

Flexion Therapeutics exotic insider transaction detected

Flexion Therapeutics insider trading alert for general transaction of employee stock option (right to buy) by Wentworth Kerry, Chief Regulatory Officer, on July 17, 2018. This event was filed by Flexion Therapeutics Inc with SEC on 2017-12-29. SEC Form: Changes in beneficial ownership [view details]   

Flexion Therapeutics Summary

Flexion Therapeutics (FLXN) is traded on BATS Exchange in USA. It is located in MASSACHUSETTS U.S.A and employs 255 people. Flexion Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Mid-Cap' category with current market capitalization of 1.04 B. Flexion Therapeutics conducts business under Healthcare sector and is part of Drugs - Generic industry. This company has 37.64 M outstanding shares of which 11.28 M shares are currently shorted by private and institutional investors with about 25.17 trading days to cover. Flexion Therapeut currently holds about 371.71 M in cash with (131.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.88.
Check Flexion Therapeutics Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Odds Below 27.42HorizonTargetOdds Above 27.42
82.95%30 days 27.42 16.84%
Based on normal probability distribution, the odds of Flexion Therapeutics to move above current price in 30 days from now is about 16.84% (This Flexion Therapeutics probability density function shows the probability of Flexion Therapeutics Stock to fall within a particular range of prices over 30 days) .

Top Holders

Selected Flexion Therapeutics Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Flexion Therapeutics Against Markets

Risk Adjusted
Performance Score (0 to 100)
3 
Chance of
Financial Distress (0 to 100%)
62 
Equity ratings for Flexion Therapeutics are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. The company was founded in 2007 and is headquartered in Burlington, Massachusetts. Flexion Therapeutics operates under Drug Manufacturers - Specialty Generic classification in USA and traded on NASDAQ General Markets. It employs 255 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Flexion Therapeutics SEC Filings
Flexion Therapeutics SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameFlexion Therapeutics
CEO, Co-Founder, Board MemberMichael ClaymanView All
Thematic Classification
Currently Active Investing Idea
  Pharmaceutical Products
View All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Specialization
Healthcare, Drug Manufacturers - Specialty & Generic
InstrumentUSA Stock View All
RegionNorth America
LocationMASSACHUSETTS U.S.A
Business Address10 Mall Road
ExchangeBATS Exchange
CIK Number0001419600
CUSIP33938J106
SectorHealthcare
IndustryDrugs - Generic
BenchmarkDOW
Websitewww.flexiontherapeutics.com
Phone781 305 7777
CurrencyUSD - US Dollar

Flexion Therapeutics Corporate Directors

Sandesh Mahatme Director
Scott Canute Director, MBA
Ann Merrifield Director
Additionally see Investing Opportunities. Please also try Portfolio Manager module to state of the art portfolio manager to monitor and improve performance of your invested capital.